Abstract
Purpose
SUM-IAP has been developed with the aim to optimize therapeutic response and minimize toxic reactions of oxazaphosphorine cytostatics. In therapy tests in mice, the primary tumor was successfully eradicated, but animals died due to formation of lethal metastases. We supposed that high activities of SUM-IAP detoxifying enzymes caused metastasis formation in the liver. Therefore, therapy tests with SUM-IAP in combination with cisplatin and N-methylformamide (NMF), which were not detoxified in the liver, were carried out.
Method
Antitumor activity was assayed in female CD2F1 mice with advanced subcutaneously growing P388 mice leukemia cells.
Result
The results of the therapy tests with SUM-IAP plus cisplatin were as expected: No formation of metastases and long-time survival of more than 100 days were observed; however, the toxicity was increased as measured by decrease in body weight and the number in leukocytes. The results of the tests in combination with NMF were surprising: Applying only half the dose of SUM-IAP used in the experiments with cisplatin, no metastases were found and long-time survivors did not show signs of additional toxicity.
Conclusion
NMF strongly enhances the antitumor activity of the oxazaphosphorine cytostatic SUM-IAP in mice with subcutaneously growing P388 mice leukemia cells by an unknown mechanism of action.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Bielicki L, Voelcker G, Hohorst HJ (1983) Enzymatic toxicogenation of activated cyclophosphamide by 3′–5′ exonucleases. J Cancer Res Clin Oncol 105:27–29
Bielicki L, Voelcker G, Hohorst HJ (1984) Activated cyclophosphamide: an enzyme- mechanism-based suicide inactivator of DNA polymerase/3′–5′ exonuclease. J Cancer Res Clin Oncol 107:195–198
Chatterjee D, Mendelsohn A, Shank PR, Savarese TM (1989) Reversible Suppression of c-myc Expression in a human colon carcinoma line by the anticancer agent N-methylformamide. Cancer Res 49:3910–3916
Clarke CA, Philips SF, Sternber SS (1953) Effects of N-methylformamide and related compounds in sarcoma 180. Proc Soc Exp Biol Med 84:203–207
Codeiro RF, Savarese TM (1986) Role of glutathione depletion in the mechanism of action of N-methylforamide and N, N-dimethylformamide in a cultured human colon carcinoma cell line. Cancer Res 46:1297–1305
Gescher A, Gibson NW, Hickman JA, Langdon SP, Ross D, Atassi G (1982) N-methylformamide: antitumor activity and metabolism in mice. Br J Cancer 45:483–485
Hohorst HJ, Bielicki L, Mülller K, Voelcker G (1988) Low toxicity cancer chemotherapy by suicide inactivation of DANN polymerase holoenzyme: first results with new thiazolidinyl- and perhydrothiazinyl-ethyl-N-mustard-phosphamide-esters. J Cancer Res Clin Oncol 114:309–311
Iwakawa M, Tofilon PJ, Hunter N, Stephens LC, Milas L (1987) Antitumor and antimetastatic activity of the differentiating agent N-methylformamide in murine tumor systems. clin Exp Metastasis 5(4):289–300
Kalyani D, Jyothi K, Sivaprakasam C, Nachiappan V (2014) Spectroscopic and molecular modeling studies on interactions of N-methylformamide with superoxide dismutase. Mol Biomol Spectrosc 124:148–152
Malorny W, Meschini S, Arancia G (1992) Cytoskeleton-dependent surface blebbing induced by the polar solvent N-methylforamide. Exp Mol Pathol 57:85–104
Meyers WPL, Karnowsky DA, Burchenal JH (1956) The hepatotoxic action of N-methylformamide in man. Cancer 9:949–954
O´Dwyer PJ, Frcsi MD, McCabe DP, Sickle-Santanello BJ, Woltering EA, Clausen K, Martin EW (1988) Use of polar solvents in chemoprevention of 1,2-dimethylhydrazin-induced colon cancer. Cancer 62:944–948
Pagnotta E, Calonghi N, Boga C, Masotti L (2005) N-methylforamide and 9-hydroxystearic acid with different modes of action I, n colon cancer cells. Anticancer Drugs 17(5):521–526
Tofilon PJ, Vines CM, Milas L (1987) The effect of N-methylformamide on artificial and spontaneous metastases from a murine hepatocarcinoma. Br J Cancer 55:239–243
Voelcker G, Hohorst HJ (1998) Structure/activity studies with thiazolidinyl- and perhydrthiazinyl phosphamide esters. J Cancer Res Clin Oncol 124:297–300
Voelcker G, Bielicki L, Hohorst HJ (1981) Evidence for enzymatic toxification of activated Cyclophosphamide (4-hydroxycyclophosphamide). J Cancer Res Clin Oncol 99A:58–59
Watanabe K, Shibuya S, Koyama H, Ozawa Y, Toda T, Yokote K, Shimizu T (2013) Sod1 loss induces intrinsic superoxide accumulation leading to p53-mediated growth arrest and apoptosis. Int J Mol Sci 14:10998–11010
Wood AC, Elvin P, Hickman JA (1995) Induction of apoptosis by anti cancer drugs with disperate modes of action: kinetics of cell death and changes in c-myc expression. Br J Cancer 71:937–941
Zimmermann J, Bauer HH, Hohorst HJ, Voelcker G (2000) Synthesis of I-aldophosphamide-perydrothiazines. Arzneimittelforschung 50(9):843–847
Acknowledgments
For critical review and proof reading of the manuscript, I thank Prof. Frank Nürnberger and Prof. Stefan Müller Goethe University Frankfurt, Medical School, Frankfurt am Main, Germany.
Funding
This study was funded by the Bundesministerium für Forschung und Technologie.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The author declares no conflict of interest.
Ethical approval
All applicable international, national and institutional guidelines for the care and use of animals were followed.
Additional information
Dedicated to Prof. Dr. Hans Jürgen Hohorst (March 14, 1924–January 10, 2015).
Rights and permissions
About this article
Cite this article
Voelcker, G. Enhancement of antitumor activity of the oxazaphosphorine cytostatic SUM-IAP by N-methylformamide. J Cancer Res Clin Oncol 142, 1183–1189 (2016). https://doi.org/10.1007/s00432-016-2132-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00432-016-2132-5